Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market

REFERENCES

• Bruce R D, Altice F L, Friedland G H. HIV Disease among Substance Users: Treatment Issues. Global HIV/AIDS Medicine, P Volberding. Elsevier, New York 2007
   Google Scholar
• Bruce R D, Altice F L. Clinical care of the HIV-infected drug user. Infect Dis Clin North Am 2007; 21: 149–179; ix
   PubMed Web of Science ®Google Scholar
• Auriacombe M, Fatseas M, Dubernet J, Daulouede J P, Tignol J. French field experience with buprenorphine. American Journal on Addictions 2004; 13(Suppl 1)S17–28
   PubMed Web of Science ®Google Scholar
• Jenkinson R A, Clark N C, Fry C L, Dobbin M. Buprenorphine diversion and injection in Melbourne, Australia: an emerging issue?. Addiction 2005; 100: 197–205
   PubMed Web of Science ®Google Scholar
• Loo H W, Yam A K, Tan T C, Peng Y P, Teoh L C. Severe upper limb complications from parenteral abuse of Subutex. Ann Acad Med Singapore 2005; 34: 575–578
   PubMedGoogle Scholar
• Lai S H, Teo C E. Buprenorphine-associated deaths in Singapore. Ann Acad Med Singapore 2006; 35: 508–511
   PubMedGoogle Scholar
• Lee C E. Tackling Subutex abuse in Singapore. Singapore Med J 2006; 47: 919–921
   PubMedGoogle Scholar
• Lo H Y, Leong C S. Surgical complications in parenteral Subutex abusers. Singapore Med J 2006; 47: 924–927
   PubMedGoogle Scholar
• Chua S M, Lee T S. Abuse of prescription buprenorphine, regulatory controls and the role of the primary physician. Ann Acad Med Singapore 2006; 35: 492–495
   PubMedGoogle Scholar
• Winslow M, Subramaniam M, Ng W L, Lee A, Song G, Chan Y H. Seroprevalence of hepatitis C in intravenous opioid users presenting in the early phase of injecting drug use in Singapore. Singapore Med J 2007; 48: 504–508
   PubMedGoogle Scholar
• Winslow M, Ng W L, Mythily S, Song G, Yiong H C. Socio-demographic profile and help-seeking behaviour of buprenorphine abusers in Singapore. Ann Acad Med Singapore 2006; 35: 451–456
   PubMedGoogle Scholar
• Ng W L, Mythily S, Song G, Chan Y H, Winslow M. Concomitant use of midazolam and buprenorphine and its implications among drug users in Singapore. Ann Acad Med Singapore 2007; 36: 774–777
   PubMed Web of Science ®Google Scholar
• Loo H W, Yam A K, Tan T C, Peng Y P, Teoh L C. Severe upper limb complications from parenteral abuse of Subutex. Annals of the Academy of Medicine, Singapore 2005; 34: 575–578
   PubMedGoogle Scholar
• Obadia Y, Perrin V, Feroni I, Vlahov D, Moatti J P. Injecting misuse of buprenorphine among French drug users. Addiction 2001; 96: 267–272
   PubMed Web of Science ®Google Scholar
• Robinson G M, Dukes P D, Robinson B J, Cooke R R, Mahoney G N. The misuse of buprenorphine and a buprenorphine-naloxone combination in Wellington, New Zealand. Drug and Alcohol Dependence 1993; 33: 81–86
   PubMed Web of Science ®Google Scholar
• Nigam A K, Srivastava R P, Saxena S, Chavan B S, Sundaram K R. Naloxone-induced withdrawal in patients with buprenorphine dependence. Addiction 1994; 89: 317–320
   PubMedGoogle Scholar
• Harris D S, Jones R T, Welm S, Upton R A, Lin E, Mendelson J. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug and Alcohol Dependence 2000; 61: 85–94
   PubMed Web of Science ®Google Scholar
• Singh R A, Mattoo S K, Malhotra A, Varma V K. Cases of buprenorphine abuse in India. Acta Psychiatrica Scandinavica 1992; 86: 46–48
   PubMed Web of Science ®Google Scholar
• Villiger J W, Taylor K M. Buprenorphine: high-affinity binding to dorsal spinal cord. Journal of Neurochemistry 1982; 38: 1771–1773
   PubMedGoogle Scholar
• Huang P, Kehner G B, Cowan A, Liu-Chen L-Y. Comparison of Pharmacological Activities of Buprenorphine and Norbuprenorphine: Norbuprenorphine Is a Potent Opioid Agonist. J Pharmacol Exp Ther 2001; 297: 688–695
   PubMed Web of Science ®Google Scholar
• Cowan A. Buprenorphine: New pharmacological aspects. International Journal of Clinical Practice 2003; 3–8, (Supplement): discussion 23-24
   PubMedGoogle Scholar
• Mcance-Katz E, Moody D E, Morse G D, Pade P, Baker J, Alvanzo A, Smith P, Ogundele A, Jatlow P, Rainey P M. Interactions between Buprenorphine and Antiretrovirals. I. The Nonnucleoside Reverse-Transcriptase Inhibitors Efavirenz and Delavirdine. Clinical Infectious Diseases 2006; 43: S224–S234
   Google Scholar
• Bruce R D, Govindasamy S, Sylla L, Haddad M S, Kamarulzaman A, Altice F L. Case series of buprenorphine injectors in Kuala Lumpur, Malaysia. Am J Drug Alcohol Abuse 2008; 34: 511–517
   PubMed Web of Science ®Google Scholar
• Mendelson J, Upton R A, Everhart E T, Jacob P, 3rd, Jones R T. Bioavailability of sublingual buprenorphine. Journal of Clinical Pharmacology 1997; 37: 31–37
   PubMed Web of Science ®Google Scholar
• Ahmadi J, Ahmadi K. Controlled trial of maintenance treatment of intravenous buprenorphine dependence. Irish Journal of Medical Science 2003; 172: 171–173
   PubMedGoogle Scholar
• Ahmadi J, Ahmadi K, Ohaeri J. Controlled, randomized trial in maintenance treatment of intravenous buprenorphine dependence with naltrexone, methadone or buprenorphine: A novel study. European Journal of Clinical Investigation 2003; 33: 824–829
   PubMed Web of Science ®Google Scholar